Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Galasko

Showing results (11-20 of 275) with videos related to

Pageof 28
Sort By:
EJIFCC|January 25, 2019
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical ChemistryKaj Blennow, Douglas Galasko
The New England Journal of Medicine|November 30, 2022
Lack of Benefit of Iron Chelation in Early Parkinson's DiseaseDouglas Galasko, Tanya Simuni
The Lancet. Neurology|March 19, 2022
Dynamics of neuroinflammation in Alzheimer's diseaseDenis Smirnov, Douglas Galasko
Alzheimer'S Research & Therapy|June 1, 2020
A decade of Alzheimer's Research & Therapy: reflections on the past, present, and futureDouglas Galasko, Philip Scheltens
Neurology|June 12, 2002
Picking away at frontotemporal dementiaDouglas Galasko, Karen Marder
Biomarkers in Medicine|April 13, 2010
Biomarkers of oxidative damage and inflammation in Alzheimer's diseaseDouglas Galasko, Thomas J Montine
Annals of Neurology|August 24, 2023
Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and ADLeslie M Shaw, Douglas Galasko
JAMA|March 13, 2008
Primary care screening for dementia and mild cognitive impairmentMichael S Rafii, Douglas Galasko
Alzheimer'S Research & Therapy|March 9, 2013
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problemsDouglas Galasko, Todd E Golde
JAMA|August 30, 2008
Guest authorship, mortality reporting, and integrity in rofecoxib studiesSteven Ferris, Douglas Galasko, Louis Kirby
Pageof 28

Showing results (11-20 of 275) with videos related to

Sort By:
Pageof 28
EJIFCC|January 25, 2019
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical ChemistryKaj Blennow, Douglas Galasko
The New England Journal of Medicine|November 30, 2022
Lack of Benefit of Iron Chelation in Early Parkinson's DiseaseDouglas Galasko, Tanya Simuni
The Lancet. Neurology|March 19, 2022
Dynamics of neuroinflammation in Alzheimer's diseaseDenis Smirnov, Douglas Galasko
Alzheimer'S Research & Therapy|June 1, 2020
A decade of Alzheimer's Research & Therapy: reflections on the past, present, and futureDouglas Galasko, Philip Scheltens
Neurology|June 12, 2002
Picking away at frontotemporal dementiaDouglas Galasko, Karen Marder
Biomarkers in Medicine|April 13, 2010
Biomarkers of oxidative damage and inflammation in Alzheimer's diseaseDouglas Galasko, Thomas J Montine
Annals of Neurology|August 24, 2023
Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and ADLeslie M Shaw, Douglas Galasko
JAMA|March 13, 2008
Primary care screening for dementia and mild cognitive impairmentMichael S Rafii, Douglas Galasko
Alzheimer'S Research & Therapy|March 9, 2013
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problemsDouglas Galasko, Todd E Golde
JAMA|August 30, 2008
Guest authorship, mortality reporting, and integrity in rofecoxib studiesSteven Ferris, Douglas Galasko, Louis Kirby
Pageof 28